NCT05626296 Molecular Network Characteristics of Phlegm-heat Syndrome in Ischemic Stroke Based on Multi-omics Integrated Analysis
| NCT ID | NCT05626296 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dongzhimen Hospital, Beijing |
| Condition | Ischemic Stroke, Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 24 participants |
| Start Date | 2022-11-14 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 24 participants in total. It began in 2022-11-14 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.
Eligibility Criteria
Inclusion Criteria: * Acute ischemic stroke, were confirmed by magnetic resonance imaging (MRI). * Symptom onset within 72 hours. * Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome. * Male or female ≥ 50 years and ≤ 80 years. * With written informed consent. Exclusion Criteria: * Planned or already receiving intravenous thrombolysis or endovascular treatment. * Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment. * Patients with previous stroke. * Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases. * Other conditions that may affect the collection and evaluation of clinical information (e.g., severe aphasia, mental illness).
Frequently Asked Questions
Who can join the NCT05626296 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Ischemic Stroke, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05626296 currently recruiting?
Yes, NCT05626296 is actively recruiting participants. Visit ClinicalTrials.gov or contact Dongzhimen Hospital, Beijing to inquire about joining.
Where is the NCT05626296 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05626296 clinical trial?
NCT05626296 is sponsored by Dongzhimen Hospital, Beijing. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.